Provista Dx Raises $6M | GenomeWeb

NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Provista Diagnostics today announced the closing of a financing round bringing in $6 million. 

Funding from the Series A-2 Preferred financing round came from existing investors exercising warrants from a previous financing round, the New York-based company said, adding that proceeds will be used for continued commercial development, prospective clinical trials, key management hires, and general corporate purposes. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.